Pfizer, Inc.





Real-time Estimate Cboe BZX 01:11:46 2023-12-11 pm EST Intraday chart for Pfizer, Inc. 5-day change 1st Jan Change
28.52 USD -0.92% -2.53% -44.30%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Steady in Afternoon Trading MT
Top Stories at Midday: Unemployment Rate Falls; Carrier Global Rises on Honeywell Deal; Tesla's Norway Labor Woes; FDA Approves Casgevy, Lyfgenia; Putin's 2024 Presidential Run MT
Pfizer Secures Conditional Marketing Approval from EU for Blood Cancer Therapy MT
Pfizer obtains EU marketing authorization for multiple myeloma CF
Pfizer's Multiple Myeloma Drug Elrexfio Receives Conditional Marketing Approval From European Commission MT
Pfizer Gets Europe OK for Elrexfio in Multiple Myeloma DJ
European Commission Approves Pfizer's ELREXFIO for Relapsed and Refractory Multiple Myeloma CI
US Equity Markets Close Higher Thursday Following Jobless Claims, Wholesale Inventories Data MT
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say RE
Bain scores over tenfold return with $8.7 billion Cerevel sale RE
US sets policy to seize patents of government-funded drugs if price deemed too high RE
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook MT
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs MT
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research MT
US sets policy to seize government-funded drug patents if price deemed too high RE
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate MT
AbbVie to buy drug developer Cerevel for $8.7 billion RE
Pfizer: 'encouraging' data in breast cancer CF
Health Canada authorizes Novavax's updated COVID shot for Omicron RE
Arvinas, Pfizer Report Clinical Data for Vepdegestrant Combined With Palbociclib in Breast Cancer Treatment MT
Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program CI
Altimmune open to partnerships, deals with drugmakers, says CEO RE
Pfizer: recruitment completed for VALOR trial CF
BridgeBio Seeks FDA Approval of Acoramidis in Transthyretin Amyloid Cardiomyopathy DJ
Chart Pfizer, Inc.
More charts
Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines (52.4%); - drugs for the treatment of cancer (15.2%); - cardiovascular, metabolic and analgesic drugs (11.5%); - injectable, anti-infectives drugs and active pharmaceutical ingredients (9%); - drugs for inflammatory and immune diseases (5.5%); - drugs for rare diseases (4.4%); - other (2%). At the end of 2021, the group had more than 39 production sites worldwide. Net sales are distributed geographically as follows: the United States (36.6%), Europe (22.6%) and other (40.8%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-44.30% 163 B $
+58.30% 538 B $
+42.69% 430 B $
-12.46% 372 B $
-6.24% 264 B $
-5.98% 263 B $
-12.46% 232 B $
+2.38% 198 B $
+3.47% 144 B $
-2.27% 116 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Pfizer, Inc. - Nyse
  4. News Pfizer, Inc.
  5. Pfizer's Rocky Mount, North Carolina, Facility Restarts Majority of Production After July Tornado
As early as today, start finding the best investment opportunities!
Optimize my profits